170 related articles for article (PubMed ID: 38509588)
1. SGLT2 inhibition, high-density lipoprotein, and kidney function: a mendelian randomization study.
Wang Z; Wei J; Zhao W; Shi R; Zhu Y; Li X; Wang D
Lipids Health Dis; 2024 Mar; 23(1):84. PubMed ID: 38509588
[TBL] [Abstract][Full Text] [Related]
2. SGLT2 inhibition, circulating metabolites, and atrial fibrillation: a Mendelian randomization study.
Li J; Yu Y; Sun Y; Yu B; Tan X; Wang B; Lu Y; Wang N
Cardiovasc Diabetol; 2023 Oct; 22(1):278. PubMed ID: 37848934
[TBL] [Abstract][Full Text] [Related]
3. Allometric body shape indices, type 2 diabetes and kidney function: A two-sample Mendelian randomization study.
Kjaergaard AD; Krakauer J; Krakauer N; Teumer A; Winkler TW; Ellervik C
Diabetes Obes Metab; 2023 Jul; 25(7):1803-1812. PubMed ID: 36855799
[TBL] [Abstract][Full Text] [Related]
4. HDL Cholesterol, LDL Cholesterol, and Triglycerides as Risk Factors for CKD: A Mendelian Randomization Study.
Lanktree MB; Thériault S; Walsh M; Paré G
Am J Kidney Dis; 2018 Feb; 71(2):166-172. PubMed ID: 28754456
[TBL] [Abstract][Full Text] [Related]
5. Obesity and Kidney Function: A Two-Sample Mendelian Randomization Study.
Kjaergaard AD; Teumer A; Witte DR; Stanzick KJ; Winkler TW; Burgess S; Ellervik C
Clin Chem; 2022 Mar; 68(3):461-472. PubMed ID: 34922334
[TBL] [Abstract][Full Text] [Related]
6. SGLT2 Inhibition, Choline Metabolites, and Cardiometabolic Diseases: A Mediation Mendelian Randomization Study.
Xu M; Zheng J; Hou T; Lin H; Wang T; Wang S; Lu J; Zhao Z; Li M; Xu Y; Ning G; Bi Y; Wang W
Diabetes Care; 2022 Nov; 45(11):2718-2728. PubMed ID: 36161993
[TBL] [Abstract][Full Text] [Related]
7. Type 2 Diabetes, Diabetes Genetic Score and Risk of Decreased Renal Function and Albuminuria: A Mendelian Randomization Study.
Xu M; Bi Y; Huang Y; Xie L; Hao M; Zhao Z; Xu Y; Lu J; Chen Y; Sun Y; Qi L; Wang W; Ning G
EBioMedicine; 2016 Apr; 6():162-170. PubMed ID: 27211558
[TBL] [Abstract][Full Text] [Related]
8. Diabetes mellitus, glycemic traits, SGLT2 inhibition, and risk of pulmonary arterial hypertension: A Mendelian randomization study.
Tan JS; Yang Y; Wang J; Wang Y; Lv T; Shu Y; Xu W; Chong L
Biosci Trends; 2024 Mar; 18(1):94-104. PubMed ID: 38325821
[TBL] [Abstract][Full Text] [Related]
9. The effect of sodium glucose cotransporter 2 inhibition with empagliflozin on microalbuminuria and macroalbuminuria in patients with type 2 diabetes.
Cherney D; Lund SS; Perkins BA; Groop PH; Cooper ME; Kaspers S; Pfarr E; Woerle HJ; von Eynatten M
Diabetologia; 2016 Sep; 59(9):1860-70. PubMed ID: 27316632
[TBL] [Abstract][Full Text] [Related]
10. The causal effects of lipid traits on kidney function in Africans: bidirectional and multivariable Mendelian-randomization study.
Kintu C; Soremekun O; Kamiza AB; Kalungi A; Mayanja R; Kalyesubula R; Bagaya S B; Jjingo D; Fabian J; Gill D; Nyirenda M; Nitsch D; Chikowore T; Fatumo S
EBioMedicine; 2023 Apr; 90():104537. PubMed ID: 37001235
[TBL] [Abstract][Full Text] [Related]
11. Effects of sodium-glucose co-transporter 2 (SGLT2) inhibitors on renal outcomes in patients with type 2 diabetes mellitus and chronic kidney disease: A protocol for systematic review and meta-analysis.
Yu B; Dong C; Hu Z; Liu B
Medicine (Baltimore); 2021 Feb; 100(8):e24655. PubMed ID: 33663074
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of the Effect of Sodium-Glucose Cotransporter 2 Inhibition on Fracture Risk: Evidence From Mendelian Randomization and Genetic Association Study.
Dai H; Zheng L; Zhu Z; Geng X; Hou T; Wang Q; Zhu Y; Lin H; Wang S; Zheng R; Zhao Z; Li M; Lu J; Xu Y; Wang T; Liu J; Ning G; Wang W; Bi Y; Zheng J; Xu M
J Bone Miner Res; 2023 Nov; 38(11):1645-1653. PubMed ID: 37436694
[TBL] [Abstract][Full Text] [Related]
13. Initiation of the SGLT2 inhibitor canagliflozin to prevent kidney and heart failure outcomes guided by HbA1c, albuminuria, and predicted risk of kidney failure.
Tye SC; Jongs N; Coca SG; Sundström J; Arnott C; Neal B; Perkovic V; Mahaffey KW; Vart P; Heerspink HJL
Cardiovasc Diabetol; 2022 Sep; 21(1):194. PubMed ID: 36151557
[TBL] [Abstract][Full Text] [Related]
14. The causal relationship between COVID-19 and estimated glomerular filtration rate: a bidirectional Mendelian randomization study.
Li Q; Lin M; Deng Y; Huang H
BMC Nephrol; 2024 Jan; 25(1):21. PubMed ID: 38225574
[TBL] [Abstract][Full Text] [Related]
15. Using Mendelian randomization study to assess the renal effects of antihypertensive drugs.
Zhao JV; Schooling CM
BMC Med; 2021 Mar; 19(1):79. PubMed ID: 33766008
[TBL] [Abstract][Full Text] [Related]
16. SGLT2 inhibitor empagliflozin reduces renal growth and albuminuria in proportion to hyperglycemia and prevents glomerular hyperfiltration in diabetic Akita mice.
Vallon V; Gerasimova M; Rose MA; Masuda T; Satriano J; Mayoux E; Koepsell H; Thomson SC; Rieg T
Am J Physiol Renal Physiol; 2014 Jan; 306(2):F194-204. PubMed ID: 24226524
[TBL] [Abstract][Full Text] [Related]
17. The citrate transporter SLC13A5 as a therapeutic target for kidney disease: evidence from Mendelian randomization to inform drug development.
Gill D; Zagkos L; Gill R; Benzing T; Jordan J; Birkenfeld AL; Burgess S; Zahn G
BMC Med; 2023 Dec; 21(1):504. PubMed ID: 38110950
[TBL] [Abstract][Full Text] [Related]
18. The kidney and cardiovascular outcome trials.
Bloomgarden Z
J Diabetes; 2018 Feb; 10(2):88-89. PubMed ID: 29031006
[TBL] [Abstract][Full Text] [Related]
19. Hypothyroidism and Kidney Function: A Mendelian Randomization Study.
Ellervik C; Mora S; Ridker PM; Chasman DI
Thyroid; 2020 Mar; 30(3):365-379. PubMed ID: 31910748
[No Abstract] [Full Text] [Related]
20. Genetically determined blood lead is associated with reduced renal function amongst individuals with type 2 diabetes mellitus: insight from Mendelian Randomisation.
Mazidi M; Kirwan R; Davies IG
J Mol Med (Berl); 2022 Jan; 100(1):125-134. PubMed ID: 34661687
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
